parimifasor is a novel broad-spectrum anti-tumor drug
RNA-seq (gene expression) · human · 12 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 12 samples: 3 × kc vs 3 × kd vs 3 × lc vs 3 × ldGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE301734_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1287494 and SRA study SRP598583. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 12 samples.
How we read this: 4 replicated groups read from 12 sample titles; they account for 12 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9088188 kc_1 kc
- GSM9088189 kc_2 kc
- GSM9088190 kc_3 kc
- GSM9088191 kd_1 kd
- GSM9088192 kd_2 kd
- GSM9088193 kd_3 kd
- GSM9088194 lc_1 lc
- GSM9088195 lc_2 lc
- GSM9088196 lc_3 lc
- GSM9088197 ld_1 ld
- GSM9088198 ld_2 ld
- GSM9088199 ld_3 ld
- GSE261648 Unraveling Novel Drug candidate for ALS through an Integrative Network Analysis of approved Drug-Gene Expression Signatures in Human Pluripotent Stem Cell-Based Model 151 samples shares drug
- GSE264741 Functional Screening and Transcriptomic Analysis Identify Novel Druggable Dependencies and Immunotherapy Targets in Desmoplastic Small Round Cell Tumor 124 samples shares drug
- GSE314304 IL-11 receptor is a novel target for drug development with pharmacological activity in fibro-inflammatory disease 96 samples shares drug
- GSE255617 Development of novel Hepatocellular Carcinoma drugs, JNK-IN-5A derivatives simultaneously induce Apoptosis and Necrosis 40 samples shares drug
- GSE281471 Targeting CD206+ macrophages disrupts the establishment of a key anti-tumor immune axis [Bulk RNA-seq] 243 samples shares anti-tumor
- GSE243841 Peripheral mRNA expression of first-episode drug-naïve patients with schizophrenia 181 samples shares drug
- GSE256068 Identification of gene regulatory networks affected across drug-resistant epilepsies 162 samples shares drug
- GSE275078 In vitro drug screening of RAF/MEK/ERK Inhibitors in combination with Autophagy inhibition in the context of two PDA Cell Lines 136 samples shares drug
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.